News Articles

Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy SIOUX FALLS, S.D. -Friday 17 August 2018  

(BUSINESS WIRE)-- SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious...

First Treatment for MERS Appears Safe in NIH Phase I Clinical Trial -Thursday 11 January 2018

(BUSINESS WIRE) -- SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical development company, announced its anti-MERS immunotherapy (SAB-301) appears safe in a Phase I Clinical Trial. Results of the study, sponsored, funded and conducted by National Institutes of Health (NIH) were...

SAB Biotherapeutics' Immunotherapy Proposal among Top Platform Technology Solutions in WHO Report -Wednesday 21 September 2016

(BUSINESS WIRE)-- SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company, announced today that its DiversitAb human antibody production platform, leveraging transchromosomic cattle (Tc Bovine™), was identified as of one of the six most meritorious proposals...

SAB Biotherapeutics Announces Contract with BARDA to Advance First MERS Treatment -Thursday 25 August 2016

(BUSINESS WIRE)-- SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical development company, announced today that it has been awarded a contract for up to $5.3 million by the Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant...

Phase I Clinical Trials Underway for First MERS Treatment -Thursday 11 August 2016

(BUSINESS WIRE)-- SAB Biotherapeutics, Inc. (SAB), a leading biopharmaceutical development company, announced today that Phase I Clinical Trials are underway for its human antibody treatment (SAB-301) for MERS-CoV. The goal of the study–sponsored, funded and conducted by National Institutes...